Reuters logo
2 个月前
BRIEF-Bristol-Myers announces availability of Orencia subcutaneous administration option for patients above 2 yrs of age with moderately to severely active polyarticular JIA
2017年6月8日 / 中午11点39分 / 2 个月前

BRIEF-Bristol-Myers announces availability of Orencia subcutaneous administration option for patients above 2 yrs of age with moderately to severely active polyarticular JIA

1 分钟阅读

June 8 (Reuters) - Bristol-myers Squibb Co

* Bristol-Myers Squibb announces availability of new Orencia (abatacept) subcutaneous administration option for patients 2 years of age and older with moderately to severely active polyarticular Juvenile Idiopathic Arthritis (JIA) Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below